Focus on paroxetine
Title
Focus on paroxetine
Creator
Green B
Identifier
Publisher
Current Medical Research And Opinion
Date
2003
Subject
Humans; Treatment Outcome; Drug Interactions; Animals; Antidepressive Agents; Stress Disorders; Anxiety Disorders/drug therapy; Depression/drug therapy; Paroxetine/administration & dosage/adverse effects/pharmacokinetics/therapeutic use; Post-Traumatic/drug therapy; Second-Generation/administration & dosage/adverse effects/pharmacokinetics/therapeutic use; Serotonin Uptake Inhibitors/administration & dosage/adverse effects/pharmacokinetics/therapeutic use; Substance Withdrawal Syndrome
Description
This review of paroxetine is based on Medline and PsycLit searches and a manual search of the available research literature. It aims to cover the pharmacology of this frequently prescribed SSRI antidepressant in terms of its indications, efficacy and adverse effects. Overall, paroxetine is a well-tolerated and safe first-line SSRI antidepressant with anxiolytic qualities. It has been found useful in depression, anxiety and other conditions such as obsessive compulsive disorder and post-traumatic stress disorder. The antidepressant has some advantages over earlier tricyclic medication in terms of a lack of cardiovascular side-effects and relative safety in overdose. Cessation of use, however, is associated with withdrawal or discontinuation symptoms and patients should be counselled as to how these might be avoided. A 3- or 4-week graded withdrawal regimen, perhaps with concomitant fluoxetine to cover serotonergic discontinuation symptoms, may be advisable.
2003
Rights
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
Journal Article
Citation List Month
Backlog
URL Address
Citation
Green B, “Focus on paroxetine,” Pediatric Palliative Care Library, accessed April 26, 2025, https://pedpalascnetlibrary.omeka.net/items/show/12709.